A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

a study on Solid Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
study ends around

Description

Summary

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.

Official Title

A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation

Keywords

Solid Tumor, Phase I Arm A, Phase I Arm B

Eligibility

You can join if…

Open to people ages 18 years and up

You CAN'T join if...

  • Malabsorption or other condition that would interfere with enteral absorption
  • Active brain metastases
  • Clinically significant cardiovascular dysfunction or liver disease

Locations

  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla California 92093-1503 United States
  • British Columbia Cancer Agency accepting new patients
    Vancouver British Columbia V5Z 4E6 Canada

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Genentech, Inc.
ID
NCT06619587
Phase
Phase 1 Solid Tumor Research Study
Study Type
Interventional
Participants
Expecting 410 study participants
Last Updated
Contact us about this trial